Octagam clinical trials
A product of Immunoglobulins, Intravenous; its studies count on that page too.
How each study uses Octagam is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- 21 May 2004 · Octagam · BLA 125062 (FDA, Purple Book)
- European Union
- 19 Jan 2006 · Kiovig · EMEA/H/C/000628 (EMA; as Immunoglobulins, Intravenous)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
9 studies that test it; most in 2009 (2)
| Year | Studies |
|---|---|
| 2002 | 1 |
| 2006 | 1 |
| 2007 | 1 |
| 2009 | 2 |
| 2017 | 1 |
| 2018 | 1 |
| 2020 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 4
Octapharma (5) · George Sakoulas, MD (1) · Sutter Health (1) · Oslo University Hospital (1) · University Hospital, Bonn (1)
Often tested with
Tested in the same studies.
Related medicines
As reviewed, each with the page that says it.
- A brand or code of Immunoglobulins, Intravenous source
Studies
Open first, then newest update. How each study uses Octagam is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 9
- Octagam 10% Therapy in COVID-19 Patients With Severe Disease ProgressionCompletedPhase 3OctapharmaNCT04400058Written as Octagam 10%
- Study Evaluating Efficacy and Safety of Octagam 10% in Patients With Dermatomyositis (Idiopathic Inflammatory Myopathy)CompletedPhase 3OctapharmaNCT02728752Written as Octagam 10%
- Study of SOC Plus IVIG Compared to SOC Alone in the Treatment of COVID-19CompletedPhase 4George Sakoulas, MDNCT04411667Written as Octagam
- Effect of IVIG on Cerebral and Retinal Amyloid in Mild Cognitive Impairment Due to Alzheimer DiseaseCompletedPhase 2Sutter HealthNCT03319810Written as Octagam 10%
- Efficacy, Safety and Kinetics Study of Octagam 10% in Primary Immunodeficiency DiseasesTerminatedPhase 3OctapharmaNCT00811174Written as Octagam 10%
- Clinical Study to Evaluate the Efficacy and Safety of Octagam 10% in Idiopathic Thrombocytopenic Purpura in AdultsCompletedPhase 3OctapharmaNCT00426270Written as Octagam 10%
- Study of Octagam (Intravenous Immunoglobulin [IVIG]) 10% on the Treatment of Mild to Moderate Alzheimer's DiseaseCompletedPhase 2OctapharmaNCT00812565Written as octagam 10%
- Effect of Intravenous Immunglobulin (IVIG) After Myocardial InfarctionCompletedPhase 3Oslo University HospitalNCT00430885Written as Octagam (IVIG)
- Efficacy of Tacrolimus and I.V.-Immunoglobulins in Rasmussen EncephalitisStatus unknownPhase 2/3University Hospital, BonnNCT00545493Written as i.v. immunoglobulins